|
Outcome
|
Injectable MTE subgroup
|
Oral MTE subgroup
|
Interaction P value
|
|---|
|
No. of studies
|
Estimate (95% CI)
|
I2
|
No. of studies
|
Estimate (95% CI)
|
I2
|
|---|
|
Response to treatment
|
12
|
POR 2.02 (1.58–2.58)
|
0%
|
2
|
POR 1.94 (1.04–3.60)
|
0%
|
0.90
|
|
Performance status
|
7
|
POR 2.94 (1.99–4.34)
|
0%
|
1
|
POR 4.31 (1.89–9.84)
|
0%
|
0.41
|
|
Leukopenia
|
12
|
RR 0.68 (0.57–0.82)
|
42%
|
3
|
RR 0.57 (0.36–0.90)
|
44%
|
0.48
|
|
Thrombocytopenia
|
11
|
RR 0.67 (0.49–0.93)
|
33%
|
2
|
RR 0.42 (0.11–1.59)
|
69%
|
0.50
|
|
Nausea/vomiting
|
9
|
RR 0.82 (0.71–0.94)
|
0%
|
2
|
RR 0.47 (0.29–0.78)
|
0%
|
0.04
|
|
Hepatic injury
|
9
|
RR 0.83 (0.62–1.12)
|
19%
|
2
|
RR 0.61 (0.39–0.95)
|
0%
|
0.25
|
- Note: Subgroup analysis was unavailable for anemia, diarrhea, constipation, kidney injury, peripheral neurotoxicity, and oral mucosal lesions because all trials that assessed these outcomes used injectable Marsdenia tenacissima extract
- Abbreviations: MTE Marsdenia tenacissima extract; POR proportional odds ratio; RR risk ratio; CI confidence interval
